PubMed Health⌕ Search

Biomedical subjects

C Biedermann

Publications and source records attributed to C Biedermann.

10 recordsLinked to original sources
PubMed1989

[Therapy of metastatic prostatic cancer by orchiectomy plus Anandron versus orchiectomy plus placebo. Initial results of a randomized multicenter study].

In the course of a randomized double blind trial conducted by 7 Swiss urological centres, 51 patients with advanced, not pretreated carcinoma of the prostate were included. Following orchiectomy the patients were either administered 300 mg Anandron daily (Roussel RU 23908) or Placebo. Twelve months later the Anandron-group shows a slightly better objective response whereas there is no difference in survival rates. The adverse effects of Anandron-treatment are described.

Aged↗
PubMed1988

Treatment of superficial bladder tumors with intravesical recombinant interferon alpha-2a.

In a prospective study, the toxicity and efficacy of an instillation therapy with recombinant interferon alpha-2a (rIFN-alpha-2a) were evaluated in 12 patients with superficial bladder tumors. Treatment consisted of 8 weekly instillations of 54 X 10(6) IU rIFN-alpha-2a in 50 ml saline. Two weeks after completion of the instillation therapy, the tumor status was assessed with cystoscopy, biopsy and bladder wash-out cytology. Two partial responses, 1 no change and 2 progressive disease were seen in the 5 patients with TA tumors. In the 4 patients with carcinoma in situ, 1 complete response, 1 partial response and 2 no change were observed. Three patients suffered from carcinoma in situ and superficial papillary tumors, 1 showed complete response of the carcinoma in situ but no change of the TA tumor, the other 2 patients showed progressive disease. Three patients with partial response received a follow-up combination therapy with interferon intravesically and etretinate orally (25 mg/day). These patients presented progressive disease or no change 10 weeks after starting the follow-up combination therapy. During the treatment period, no side effects of interferon or changes of the serum interferon levels were observed. The treatment results are considered unsatisfactory; nevertheless, some activity after intravesical administration of interferon (mainly in patients with carcinoma in situ) could be demonstrated. Since the cytotoxic and antiproliferative effects seem to be dose-dependent, further studies might be done using higher interferon dosages and shorter treatment intervals.

Administration, Intravesical↗
PubMed1984

[Orchidectomy only for stage I testicular teratoma?].

In the past few years the therapeutic options for non-seminomatous germ-cell tumors of the testis have evolved rapidly. Until recently it was usual practice with patients in clinical stage I to perform lymphadenectomy or retroperitoneal radiotherapy after orchidectomy. However, for 60-80% of these patients this therapy was not necessary, since they were already cured by orchidectomy alone. With the improvement of clinical staging and the success of modern chemotherapy, it seems to be possible to follow up stage I patients clinically. The various aspects which justify this "wait-and-see" strategy are discussed. Further, the question is discussed whether all patients in clinical stage I may be treated in this way, or whether specific groups at severe risk of metastatic disease at the time of orchidectomy should be excluded.

Castration↗
PubMed1984

Prevention of recurrent superficial bladder tumors by oral etretinate: preliminary results of a randomized, double blind multicenter trial in Switzerland.

Retinoids influence the proliferation and differentiation of epithelial tissues. Preliminary results of a double-blind randomized trial in the prevention of recurrent superficial bladder tumors are promising. Patients treated with an oral etretinate tend to have less tumor recurrences and transurethral resections. The number of multifocal recurrences after 12 months of treatment is significantly lower (p less than 0.02). There also are less dropouts owing to inefficacy of treatment (p less than 0.036).

Administration, Oral↗
PubMed1983

Tissue polypeptide antigen (TPA) and prostatic acid phosphatase in serum of prostatic cancer patients.

Tissue polypeptide antigen (TPA) and prostatic acid phosphatase were both detected by radioimmunoassay in the sera of a male population (age greater than 45 years) consulting the clinic for urological problems or check-up on treatment. Increased concentrations of TPA were associated mostly with advanced stages of prostatic carcinomas, parallel to PAP. Some enhanced TPA concentrations were detected with haematuria and adenomas of the prostate.

Acid Phosphatase↗